Product
Indication
In vitro Confirmationof Lead Candidate
Efficacy Study inAnimal Model
Candidate Confirmation
Pre-clinical
Clinical
Bispecific antibody
BAB-05(CD3*CD19)
Hematological malignancies
Pre-clinical---IND expected in 2027-Q4
TCI-312(CD3*PSMA*IL-2)
Prostate Cancer
Candidate Confirmation
AF-29(IL-1R*IL-1β)
Rare disease/Acute gouty arthritis
Pre-clinical--- IND expected in 2027-Q4
lCM-053(B7H3*IL-15)
Solid/Hematological cancer
Candidate Confirmation
Antibody Conjugates
TCI-212(cMET*EGFR*PD-L1 )
NSCLC
Pre-clinical---IND expected in 2027-Q4
BTA-024(EGFR*PSMA )
Prostate Cancer
Pre-clinical
BTA-010(cMET*EGFR ）
NSCLC
Pre-clinical
Recombinant proteins
LTP-03(GLP-1/GIP/GCG)
Obesity/Diabetes
Pre-clinical
LTP-0521(GLP-1/GIP/GCG/FGF21)
MASLD/MASH
Pre-clinical